Propanc Biopharma Inc. has announced it has entered into a securities purchase agreement with Hexstone Capital LLC for a private placement of up to $100 million in convertible preferred stock. The company received an initial investment of $1 million upon closing, issuing 100 shares of newly designated Series C Convertible Preferred Stock. In addition, Propanc will issue 9,900 warrants to Hexstone, each allowing the purchase of one share of preferred stock at $10,000 per share, providing up to $99 million in potential additional funding. The funds are intended to support Propanc's digital asset acquisition strategy and accelerate its R&D pipeline, with a focus on advancing its PRP therapy to a First-In-Human study in the second half of 2026. Further details are available in the company's Form 8-K filing with the SEC.